University of California, San Francisco

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).

1,713 total trials 272 currently recruiting 1130 completed early-phase tilt top decile by trial count

University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.

University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.

Top-decile sponsor footprint

University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,713 total, page 24 of 35

COMPLETED Early Phase 1

Methadone Oxytocin Option

NCT01728909

COMPLETED NA

A Mobile Based Diabetes Prevention Program

NCT01579292

TERMINATED Phase 1

Providing "Good Sleep" for ICU Sedation

NCT01342328

TERMINATED Phase 4

Delayed Start to Ovarian Stimulation

NCT01614067

TERMINATED Phase 4

Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD)

NCT01555554

COMPLETED NA

CAMBRA - PBRN Caries Management By Risk Assessment In A Practice-Based Research Network

NCT01176396

COMPLETED NA

Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D

NCT01877577

COMPLETED NA

Healthy Mood Internet Recruitment Study

NCT01607164

COMPLETED

Assessment of Bone Micro-Architecture Using HR-pQCT

NCT01367730

COMPLETED NA

Characterization and Treatment of Chemotherapy Neuropathy

NCT01557608

COMPLETED

Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research

NCT01544660

COMPLETED Phase 4

Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients

NCT01622296

COMPLETED Phase 1

Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

NCT01554371

COMPLETED NA

Improving Care of Patients With Heart Failure

NCT01461681

COMPLETED Phase 4

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

NCT01511315

COMPLETED NA

AANCART Research Project on Lay Health Workers and Asian Americans

NCT01904890

COMPLETED Phase 1

Drug Interaction Study of Clopidogrel and Rosuvastatin

NCT01469416

COMPLETED NA

Running Against Prehypertension Trial (RAPT): A Pilot Trial

NCT01587183

COMPLETED

Dynamic Cardiac SPECT Imaging

NCT01934985

TERMINATED

UCSF Research Participant Registry

NCT01717378

COMPLETED NA

Lay Health Worker Outreach in Increasing Colorectal Cancer Screening in Asian Americans

NCT03115372

COMPLETED Phase 2

Open Label Clinical Trial of Vitamin D in Children With Autism

NCT01535508

COMPLETED Phase 4

ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study

NCT01535235

COMPLETED

Ancillary T Cell Based Studies in SPIROMICS

NCT02036190

COMPLETED Early Phase 1

Oxytocin MEG Study

NCT02568709

COMPLETED Phase 1

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

NCT01463046

COMPLETED NA

Integrative Approaches for Cancer Survivorship

NCT01488123

COMPLETED NA

Menopausal Treatment Using Relaxation Exercises (MaTURE)

NCT01466998

COMPLETED NA

Role of microRNAs in T Cell-Driven Inflammation in Asthma

NCT01484691

COMPLETED Phase 4

Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers

NCT01508832

COMPLETED

Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation

NCT01581164

COMPLETED

Clinical Diagnosis of Acute Porphyria

NCT01568554

COMPLETED Phase 1

Drug-Drug Interaction Study With Pravastatin and Cyclosporine

NCT01497483

COMPLETED NA

Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment

NCT02385786

COMPLETED NA

Post-operative Sore Throat as Determined by Endotracheal Tube Inflation Technique

NCT01305265

COMPLETED

Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

NCT01396343

COMPLETED NA

Prenatal Education About Reducing Labor Stress (PEARLS)

NCT02327559

COMPLETED NA

Prospective Femoral Versus Femoral and Sciatic Nerve Block for Anterior Cruciate Ligament (ACL) Reconstruction

NCT01447277

COMPLETED

Treatment for the Mental Health Impact of Killing in War

NCT01406834

COMPLETED NA

Effects of Sleep, Fatigue, and Timing of Post-dates Inductions Among Nulliparas

NCT01542151

COMPLETED Phase 1

Drug-drug Interaction Study With Metformin and Imatinib

NCT01404715

TERMINATED

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

NCT01452854

COMPLETED

Simons Variation in Individuals Project, Functional Common Acquisition Protocol

NCT01527578

COMPLETED Phase 1

Drug-Drug Interaction Study With Metformin and Nizatidine

NCT01409395

COMPLETED

Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging

NCT01741246

COMPLETED Phase 4

Study of Tomography of Nephrolithiasis Evaluation

NCT01451931

TERMINATED

Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors

NCT01474954

TERMINATED Phase 2

The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance

NCT01412216

COMPLETED NA

The Total Health Study

NCT01415206

COMPLETED Phase 1

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

NCT01398046

← Previous Page 24 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 193
Phase 2 166
Phase 3 44
Phase 4 152

What is open in the University of California, San Francisco pipeline

272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).

Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (18 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, San Francisco: open-pipeline peers nationwide

Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share University of California, San FranciscoDuke UniversityStanford UniversityVA Office of Research and DevelopmentPfizerUniversity of OregonFox Chase Cancer CenterYoungstown State UniversityECOG-ACRIN Cancer Research Group
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,713 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of California, San Francisco page

1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.

  • 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.